Sigyn Therapeutics, Inc.
SIGY· OTC
SIGYSigyn Therapeutics, Inc.
Filed Sep 5, 2025 · 10-Q · 67 days after period end · 0001641172-25-026704
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$1.45M | -$862.38K | -$723.12K | -$666.33K |
| EPS Diluted | -$0.90 | -$0.70 | -$0.67 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Sep 5, 2025 · 67 d after period end
